Curocell has finalized price negotiations for health insurance coverage of RIMQARTO, South Korea’s first domestically developed chimeric antigen receptor T-cell (CAR-T) cancer therapy. The treatment was submitted to the Ministry of Health and Welfare Health Insurance Policy Deliberation Committee (HIPDC), with a maximum reimbursement amount of 280.0161 million Korean won per dose. Coverage begins on Dec. 1, reducing eligible patients’ out-of-pocket costs to approximately 6 million Korean won and improving access for patients previously priced out of treatment. The coverage applies to adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Curocell is working with major medical institutions, including advanced general hospitals, to prepare prescriptions, cell collection and treatment administration, while establishing a coordinated supply system for stable and timely treatment.